- Home
- JHI vs GNLX Comparison
JHI vs GNLX Comparison
Compare JHI & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- GNLX
- Stock Information
- Founded
- JHI 1971
- GNLX 2001
- Country
- JHI United States
- GNLX United States
- Employees
- JHI N/A
- GNLX N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- GNLX Health Care
- Exchange
- JHI Nasdaq
- GNLX Nasdaq
- Market Cap
- JHI 123.0M
- GNLX 128.0M
- IPO Year
- JHI N/A
- GNLX 2023
- Fundamental
- Price
- JHI $14.08
- GNLX $3.78
- Analyst Decision
- JHI
- GNLX Strong Buy
- Analyst Count
- JHI 0
- GNLX 5
- Target Price
- JHI N/A
- GNLX $16.20
- AVG Volume (30 Days)
- JHI 29.5K
- GNLX 89.3K
- Earning Date
- JHI 01-01-0001
- GNLX 08-07-2025
- Dividend Yield
- JHI 6.80%
- GNLX N/A
- EPS Growth
- JHI N/A
- GNLX N/A
- EPS
- JHI 1.05
- GNLX N/A
- Revenue
- JHI N/A
- GNLX N/A
- Revenue This Year
- JHI N/A
- GNLX N/A
- Revenue Next Year
- JHI N/A
- GNLX N/A
- P/E Ratio
- JHI $12.47
- GNLX N/A
- Revenue Growth
- JHI N/A
- GNLX N/A
- 52 Week Low
- JHI $11.63
- GNLX $1.95
- 52 Week High
- JHI $13.40
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- JHI 60.43
- GNLX 62.02
- Support Level
- JHI $13.97
- GNLX $3.26
- Resistance Level
- JHI $14.13
- GNLX $3.50
- Average True Range (ATR)
- JHI 0.07
- GNLX 0.24
- MACD
- JHI -0.02
- GNLX 0.01
- Stochastic Oscillator
- JHI 64.71
- GNLX 99.47
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.